Navigation Links
Carrington Retains Milkie/Ferguson to Explore Financial Alternatives
Date:1/30/2008

IRVING, Texas, Jan. 30 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (OTC Bulletin Board: CARN) said it retained Milkie/Ferguson Investments, Inc. as its financial advisor to assist it in exploring a range of financial alternatives.

"Our hiring of a financial advisor is a continuation of our efforts to thoroughly consider our business model and all opportunities going forward," said Carlton Turner, PhD, chief executive officer of Carrington. "We have valuable technologies and assets which we believe have significant emerging potential and we look forward to working with Milkie/Ferguson on these initiatives."

About Carrington

Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally-occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington's DelSite Biotechnologies subsidiary is developing its proprietary GelSite(R) polymer technology designed to provide controlled release of peptide and protein-based drugs. A second technology Gelvac(TM) is designed for dry powder nasal delivery of vaccines without the need for preservatives, adjuvants, cold storage and shipping under cold conditions. One influenza vaccine, (H1N1 antigen) with this technology, has been stable for more than three years at room temperature.

Carrington's technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com.

About Milkie/Ferguson

Milkie/Ferguson Investments is a full-service, FINRA- and SIPC-member broker-dealer and boutique investment bank specializing in financing, fairness opinions, valuations, mergers and acquisitions. Milkie/Ferguson is distinguished by putting the client's interest first, providing senior-level attention, maximizing client value, and providing the premium level of service of top-tier investment banks. Milkie/Ferguson draws on its broad foundation and experience to create a tailored approach for each client that results in success. Among the firm's more recent engagements was as advisor to Reddy Ice Holdings, Inc on the $20 million sale of businesses unrelated to its bagged- ice focus.

Certain statements in this release concerning Carrington may be forward- looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission.

For Information Contact:

Robert Schnitzius, Chief Financial Officer

(972) 518-1300


'/>"/>
SOURCE Carrington Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Carrington Reports Third Quarter 2007 Results
2. Carrington Reports on ISO 9001:2000 Inspection
3. Carrington Laboratories Common Stock Now Trading on the OTC Bulletin Board: CARN.OB
4. Carrington and DaySpring Pharma Extend and Formalize Agreement for Distribution of Diabetic and Radiation Products Into Physician Market
5. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
6. Carrington Reports on ISO 9001:2000 Inspection at Sabila Industrial in Costa Rica
7. Carrington Completes $8 Million Financing
8. Carrington Reports Second Quarter 2007 Results
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
11. Biomoda, Inc. Retains MicroCap Management, LLC as its Lead Corporate Communications and Broker Relations Firm.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017  Seattle,s upscale Capitol Hill ... a strange place for a head lice treatment salon to ... between a Tuscan restaurant and a French bistro on E ... perfect. "We aren,t just any old lice clinic, we pride ... feel comfortable, and release some of the stigma associated with ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... published evaluation of multiple immunoassay-based threat detection technologies by researchers from the ... CANARY® biosensor threat detection technology was found to have the best level ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The Greater ... a new partnership with Compass Research . GGI's mission is to advance global ... to a child in need in honor of each clinical trial volunteer. The vision ...
(Date:2/23/2017)... SAN DIEGO and SAN FRANCISCO ... , a privately-held regenerative medicine company, and Beyond Type ... living with type 1 diabetes, today announced a grant ... develop a functional cure for type 1 and other ... decade, ViaCyte has been developing innovative stem cell-derived cell ...
Breaking Biology Technology:
(Date:2/7/2017)... 7, 2017   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... innovative, highly flexible and award winning eClinical solution, is ... iMedNet is a proven Software-as-a-Service (SaaS) clinical research ... (EDC), but also delivers an entire suite of eClinical ...
(Date:2/7/2017)... February 7, 2017 Ipsidy Inc. ... Corporation [OTC: IDGS], ("Ipsidy" or the "Company") a provider ... processing services, is pleased to announce the following changes ... Effective January 31, 2017, Philip D. Beck ... CEO and President.  An experienced payment industry professional and ...
(Date:2/3/2017)... -- Texas Biomedical Research Institute announced that its Board of Trustees ... the Institute,s new President and CEO. Dr. Schlesinger will take ... is currently the Chair of the Department of Microbial Infection ... Biology at Ohio State University. "We are delighted ... of Texas Biomed," said Dr. James O. Rubin , ...
Breaking Biology News(10 mins):